These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20557860)

  • 1. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.
    Geisser P; Philipp E
    Clin Nephrol; 2010 Jul; 74(1):4-11. PubMed ID: 20557860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro.
    Wilhelm M; Gaillard S; Rakov V; Funk F
    Clin Nephrol; 2014 Apr; 81(4):251-8. PubMed ID: 24656315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
    Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
    Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.
    Wüthrich RP; Chonchol M; Covic A; Gaillard S; Chong E; Tumlin JA
    Clin J Am Soc Nephrol; 2013 Feb; 8(2):280-9. PubMed ID: 23124782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    J Ren Nutr; 2017 Sep; 27(5):346-354. PubMed ID: 28550969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B; Gan L; Liu B; Yuan W; Shi M; Peng A; Wang L; Chen X; Liu T; Zhang S; Wang S; Gao Q; Wang B; Zheng H; Liu C; Luo Y; Ye H; Lin H; Li Y; He Q; Zheng F; Luo P; Long G; Lu W; Li K; Yang J; Liu YC; Zhang Z; Li X; Zhang W; Zuo L
    Nephrol Dial Transplant; 2024 Sep; 39(10):1649-1661. PubMed ID: 38453435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
    Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
    Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
    BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure.
    Neven E; Corremans R; Vervaet BA; Funk F; Walpen S; Behets GJ; D'Haese PC; Verhulst A
    Nephrol Dial Transplant; 2020 Oct; 35(10):1689-1699. PubMed ID: 33022710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.
    Xie D; Ye N; Li M
    Int Urol Nephrol; 2018 May; 50(5):905-909. PubMed ID: 29294216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation phosphate binders: focus on iron-based binders.
    Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
    Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
    Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
    Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.